NAPA, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Senetek PLC , a life sciences product development company, today announced that it will report its third quarter 2006 results on Tuesday, November 14, 2006, following the close of trading.
The company will hold a conference call to discuss its third quarter results at 12:00 p.m. EST (9:00 a.m. PST) on Friday November 17, 2006. Interested parties may access the call via the following dial-in numbers: US - 1-800-690-3108 or International - 973-935-8753; conference code - 8109360. Callers are suggested to dial-in at least 5 minutes prior to the scheduled start time. A replay of the call will be available for 7 days by dialing: US - 1-877-519-4471 or International - 973-341-3080; conference code - 8109360.
About Senetek:
Senetek is a life sciences product development company with an extensive array of intellectual properties covering in excess of 2000 patented and patent applied for compounds and uses targeting the science of aging to include skincare and dermatological therapeutics, erectile dysfunction, nutrition and cancer through RNA interference technology.
The Company’s lead commercial product, Kinetin, is currently licensed and marketed by 14 pharmaceutical and cosmeceutical companies such as Valeant Pharmaceuticals and The Body Shop. In addition, the Company has entered into commercial arrangements for its proprietary anti-aging skincare compound, Zeatin, its patented combination drug treatment for erectile dysfunction, Invicorp(R), its novel drug delivery system, Reliaject(R) as well as its proprietary diagnostic monoclonal antibodies.
For additional information, please visit Senetek PLC’s Web site at http://www.senetekplc.com.
Safe Harbor Statement:
This news release contains statements that may be considered ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook for fiscal 2006 and those that might imply commercial potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K/A for the year 2005. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
KCSA Contacts: Todd Fromer / David Burke 212-896-1215 / 1258 tfromer@kcsa.com / dburke@kcsa.com
Senetek PLC
CONTACT: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or David Burke,+1-212-896-1258, dburke@kcsa.com, both of KCSA, for Senetek PLC
Web site: http://www.senetekplc.com/
